TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22863612
Drug: 4Jointz (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4Jointz (3.5 g/day, thrice daily)
Study: 20139789
Drug: Jumping once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jumping once daily (J1x)
Study: 17075991
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN‐alpha) 5 MU daily for 15 days, then three times weekly for six months
Study: 15589860
Drug: Letrozole (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (7.5 mg daily)
Study: 15589860
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (100 mg daily)
Study: 8485266
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) (> or = 7 mg.kg/day)
Study: 8485266
Drug: Low-dose ursodeoxycholic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ursodeoxycholic acid (UDCA) (< 7 mg.kg/day)
Study: 8485266
Drug: High-dose chenodeoxycholic
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chenodeoxycholic acid (CDCA) (> or = 10 mg.kg/day)
Study: 8485266
Drug: Low-dose chenodeoxycholic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chenodeoxycholic acid (CDCA) (< 10 mg.kg/day)
Study: 31172979
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w (Mw) vaccine
Study: 25341548
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical sildenafil cream
Study: 25341548
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to opposite extremity
Study: 17446014
Drug: Mixed-gender Group
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-gender Group Drug Counseling (GDC)
Study: 10192709
Drug: Clarithromycin 2
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 2 g/day and Ethambutol 20 mg/kg/day
Study: 10192709
Drug: Clarithromycin 2
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 2 g/day, Ethambutol 20 mg/kg/day, and Clofazimine 200 mg/day
Study: 7778534
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg twice daily, can be doubled to 10 mg twice daily)
Study: 2271852
Drug: Antibiotics (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (20 patients)
Study: 2271852
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (20 patients)
Study: 23246646
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactose
Study: 23246646
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g lactose
Study: 23246646
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g lactose
Study: 17319827
Drug: Higher platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher platelet dose (HDP)
Study: 17319827
Drug: Lower platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower platelet dose (LDP)
Study: 15067363
Drug: Germinated barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated barley foodstuff (GBF) 20 g daily
Study: 15067363
Drug: Germinated barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated barley foodstuff (GBF) with steroid tapering treatment
Study: 12127385
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil) treatment
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to nucleoli in acute EMS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to nucleoli in chronic EMS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to nucleoli in FS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to 5-HT in FS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to 5-HT in acute EMS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to 5-HT in EMS patients after 2 years
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to Gm1 in acute EMS patients
Study: 7981584
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to Gm1 in chronic EMS patients
Study: 7981584
Drug: Antibodies in
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies in healthy controls
Study: 2547312
Drug: Glucomannan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (1 g tid orally)
Study: 616216
Drug: Finnish sauna
Normalized name: Sana leaf
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finnish sauna bath with beta-blockade (Oxprenolol 40 mg)
Study: 31913252
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) 70 ml
Study: 26518207
Drug: Early responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early responders (both treatment arms)
Study: 22744410
Drug: 4DDOME(®) implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4DDOME(®) implant
Study: 20507399
Drug: 4-n-butylresorcinol 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-n-butylresorcinol 0.1% cream
Study: 18779478
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine, 0.4%
Study: 15877875
Drug: Aleurone flour
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleurone flour (ALF) - 175 g bread made with ALF and placebo tablet each day
Study: 20050938
Drug: Sildenafil (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50-100 mg)
Study: 10710012
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (3.5 mg/kg)
Study: 11322246
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of saquinavir plus 200 mg of zidovudine
Study: 11322246
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of saquinavir plus 200 mg of zidovudine
Study: 31766977
Drug: Crushed Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed Ticagrelor (CTIC) 180 mg
Study: 22402329
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg for four days
Study: 17237316
Drug: Fortified dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified dairy product containing eicosapentaenoic acid, docosahexaenoic acid, oleic acid, folic acid, and vitamins A, B‐6, D, and E (500 mL/d)
Study: 17237316
Drug: Semi‐skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi‐skimmed milk with added vitamins A and D (500 mL/d)
Study: 16784831
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride 1mg rapidly disintegrating tablets
Study: 16784831
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride 1mg capsules
Study: 15240527
Drug: Oral CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CEE 0.625 mg/day
Study: 15240527
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 50 microg/day
Study: 15240527
Drug: Fenretinide 100
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 100 mg/twice a day
Study: 15240527
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (both CEE and E2)
Study: 11074185
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) as add-on therapy
Study: 11074185
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) as add-on therapy
Study: 11074185
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) as add-on therapy
Study: 19517672
Drug: Intravenous piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piracetam 30 mg kg(‐1)
Study: 17090953
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) administration after 2 months of therapy
Study: 17090953
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) administration
Study: 17090953
Drug: No L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L-thyroxine (L-T4) treatment
Study: 15310558
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase type B inhibitors (MAOBIs)
Study: 11783838
Drug: Local triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local triamcinolone injection for lateral epicondylitis (<= 12 weeks)
Study: 11783838
Drug: Intraoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative steroid at discectomy
Study: 11783838
Drug: Local glycosaminoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local glycosaminoglycan polyphosphate injection for lateral epicondylitis
Study: 11783838
Drug: Intraarticular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular steroid injection for shoulder arthritis
Study: 11783838
Drug: Subacromial steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial steroid injections for rotator cuff tendinitis
Study: 11783838
Drug: Nonspecific injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific injections for painful shoulder
Study: 9395805
Drug: Sensitivity of
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity of TRAb compared to anti-thyroglobulin antibodies
Study: 9395805
Drug: Sensitivity of
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity of TRAb compared to anti-microsomal antibodies
Study: 9395805
Drug: Specificity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specificity of TRAb levels > 10.0 U/L
Study: 7957520
Drug: Transdermal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal dexmedetomidine (625 micrograms applied for 12 h)
Study: 7957520
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (2.0 micrograms.kg‐1 as dexmedetomidine hydrochloride administered as an infusion over 5 min)
Study: 7957520
Drug: Transdermal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal dexmedetomidine
Study: 19583070
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine
Study: 23723457
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose oseltamivir (150 mg twice a day)
Study: 23723457
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose oseltamivir (75 mg twice a day)
Study: 23723457
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose oseltamivir
Study: 23723457
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose oseltamivir
Study: 21986780
Drug: Methylsulfonylmethane (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (5 g daily) and boswellic acids (7.2 mg daily)
Study: 19485978
Drug: pegylated‐interferon‐alpha2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) with amantadine (200 mg/daily)
Study: 19485978
Drug: pegylated‐interferon‐alpha2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) without amantadine
Study: 17018656
Drug: Magnesium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (300 mg elemental Mg per day in two divided doses)
Study: 11166015
Drug: Standard dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dietary treatment (50% to 55% carbohydrate and 30% fat for 2 months)
Study: 30919997
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment for up to 10 years
Study: 22980301
Drug: Intravenous high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high dose of furosemide with hypertonic saline solution (HSS)
Study: 11845758
Drug: CathSim Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CathSim Intravenous Training System (CathSim ITS)
Study: 37879
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy for 12 weeks to reduce supine BP to 150/90 mmHg or below
Study: 37879
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy for 12 weeks
Study: 31843386
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg per day from the second to the twentieth day after surgery
Study: 30744676
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with placebo herbal medicine
Study: 21344144
Drug: CMV-immunoglobulins (Cytotect
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-immunoglobulins (Cytotect Biotest) for 12 months and short Ganciclovir or Valganciclovir therapy from 21th to 42th postoperative day followed by acyclovir up to 24 months
Study: 15210261
Drug: Cognitive/behavioural group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive/behavioural group (cognitive preparation plus instruction in deep breathing exercises, tongue depressor task and swallowing technique)
Study: 11171290
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous combined HRT (Kliogest(R); 2 mg of oestradiol + 1 mg of norethisterone)
Study: 3146197
Drug: L-asparaginase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase treatment
Study: 1415455
Drug: Topical fibronectin
Normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fibronectin
Study: 752876
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VM‐26 and CCNU at full dose
Study: 752876
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VM‐26 and CCNU (half dose) with daily intake of procarbazine for 20 days
Study: 752876
Drug: Radiotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy after three cycles of chemotherapy
Study: 8843633
Drug: PRP‐T and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T and DTP vaccines combined in the same syringe
Study: 8843633
Drug: PRP‐T and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T and DTP vaccines given separately
Study: 25654354
Drug: Rifampin 10
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 10 mg/kg (Control)
Study: 25489785
Drug: Rifapentine 15
Normalized name: rifapentine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine 15 mg/kg
Study: 23850060
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during an insulin tolerance test (ITT)
Study: 16476920
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg twice daily or once daily (with a 40-mg loading dose)
Study: 16476920
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg 4 times daily
Study: 9179510
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day s.l. buprenorphine
Study: 9179510
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg 70 kg i.m.) during 8 mg buprenorphine maintenance
Study: 8144233
Drug: Cobalt oxide
Normalized name: COBALT OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt oxide (insoluble cobalt compound)
Study: 3513714
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation by rotahaler
Study: 3513714
Drug: Tilting the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilting the head back during inhalation and holding the breath for 10 seconds
Study: 25155815
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (CBT) for 9 weeks
Study: 19685520
Drug: Intracoronary bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bone marrow stem cell (BMSC) therapy at 4 to 7 days
Study: 10793164
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral xemilofiban
Study: 10793164
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of oral xemilofiban
Study: 9395803
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg as a 1 ml injection 1 to 2 hours before operation
Study: 9395803
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1 ml intramuscularly before operation
Study: 9395803
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg as a 1 ml injection immediately after surgery
Study: 9395803
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1 ml intramuscularly immediately after surgery
Study: 9395803
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of pethidine given
Study: 7954480
Drug: Moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150 mg twice daily (b.i.d.)
Study: 7954480
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg three-times-daily (t.i.d.)
Study: 7954480
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg three-times-daily (t.i.d.)
Study: 7954480
Drug: Moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150 mg b.i.d. and t.i.d. groups
Study: 7483868
Drug: Hypocaloric nutrition
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric nutrition (glucose or xylitol/sorbitol-amino acid solutions)
Study: 2090557
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (group A)
Study: 3769194
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (group B)
Study: 23789216
Drug: Qi-regulating, chest-relaxing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-regulating, chest-relaxing and blood-activating therapy integrated with some Western Medicines
Study: 23789216
Drug: Simple and
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple and conventional Western Medicine alone
Study: 21479913
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg combined with vitamin D(3) 5,600 IU
Study: 18379369
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with reduced-dose carboplatin (AUC 3) and gemcitabine (1250 mg/m on days 1 and 8)
Study: 18379369
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with gemcitabine and low-dose carboplatin
Study: 11789225
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Chinese herbal medicine combined with synchronous radio- and chemotherapy) in group A
Study: 11789225
Drug: Non-synchronous radio-
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-synchronous radio- and chemotherapy in group C
Study: 9212969
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Group H)
Study: 8661572
Drug: IV glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV glucagon (1 mg)
Study: 8273637
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg oral hyoscyamine sulfate
Study: 2525326
Drug: Nicorandil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (20 mg)